Jazz Pharmaceuticals: Ziihera Validates an Oncology Re-rating — A Tactical Long with Defined Risk
Jazz Pharmaceuticals' positive Phase 3 Ziihera results have transformed its growth trajectory. The market has reacted, but Jazz still offers a compelling risk/reward: $14.6B market cap, $1.297B free cash flow and an EV/EBITDA of 13.7 imply room for multiple expansion if commercial rollouts and approvals proceed. This trade recommends a long with cl…